Natera, Inc. (NTRA) Financial Statements

Natera, Inc.

NTRA · Nasdaq

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Total Revenue	$2.31B	$1.70B	$1.08B	$820.22M	$625.49M	$391.00M	$302.33M	$257.65M
Cost of Revenue	—	—	—	—	—	—	—	$158.08M
Research & Development	$624.11M	$404.14M	$320.68M	$316.42M	$264.21M	$100.03M	$51.36M	$51.35M
Selling, General & Administrative	$1.18B	$841.31M	$618.31M	$588.59M	$511.03M	$303.63M	$206.18M	$154.87M
Operating Expenses	$2.62B	$1.92B	$1.53B	$1.36B	$1.09B	$607.28M	$418.62M	$372.28M
Operating Income	-$309.91M	-$222.29M	-$446.25M	-$541.04M	-$468.17M	-$216.28M	-$116.29M	-$114.63M
Interest Expense	$4.07M	$10.69M	$12.64M	$9.32M	$8.30M	$15.08M	$10.69M	$10.48M
Income Before Taxes	-$268.09M	-$189.73M	-$434.53M	-$546.82M	-$471.10M	-$229.65M	-$122.83M	-$127.83M
Provision for Income Taxes	-$59.93M	$695.00K	$271.00K	$978.00K	$618.00K	$98.00K	$2.00M	$321.00K
Net Income	-$208.16M	-$190.43M	-$434.80M	-$547.80M	-$471.72M	-$229.74M	-$124.83M	-$128.15M
Basic EPS	-$1.52	-$1.53	-$3.78	-$5.57	-$5.21	-$2.84	-$1.79	-$2.22
Diluted EPS	-$1.52	-$1.53	-$3.78	-$5.57	-$5.21	-$2.84	-$1.79	-$2.22
Basic Shares Outstanding	136.72M	124.72M	115.00M	98.41M	90.56M	81.01M	69.56M	57.85M
Diluted Shares Outstanding	136.72M	124.72M	115.00M	98.41M	90.56M	81.01M	69.56M	57.85M

Analyst Estimates

Period	Consensus EPS	Low	High	Estimates	Revisions
Dec 2026	-$1.02	-$1.20	-$0.55	4	↑0 ↓0
Dec 2027	$0.01	-$0.05	$0.08	4	↑0 ↓0
Dec 2028	$1.80	$1.70	$1.89	3	↑0 ↓0

Forward estimates are the sell-side consensus reported by Nasdaq, not a metir forecast.

Symbol: NTRA
Type: Stock
Sector: Health Care
Industry: Services-Medical Laboratories
Exchange: Nasdaq

Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas , and San Carlos, California , and through Foresight Diagnostics , its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Key Issues

Bullish view

The PMDA filing could broaden Signatera’s addressable market by enabling companion-diagnostic use in Japanese muscle-invasive bladder cancer.

Bearish view

The filing is only an application, not an approval, and the evidence gives no timetable, commercial terms, or expected revenue contribution.

Analyst Consensus

See all

Buy

14 analysts

$342

Current

—

Low

$350

Average

—

High

Average target implies +2.34% versus the current price.

Earnings History

BeatMissNo estimate

Natera, Inc.

Analyst Estimates

Peers